Onco Wiki / Maladie

Leucémie myéloïde chronique (BCR-ABL1)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-CML
TypeMaladie
Alias
CMLLeucémie myéloïde chroniqueLeucémie myélogène chroniquePh+ CMLХронічна мієлоїдна лейкемія (BCR-ABL1)Хронічний мієлолейкоз
Étatreviewed 2026-04-25 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-ELN-CML-2020 SRC-ESMO-CML-2017 SRC-NCCN-MPN-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology9863/3
icd_o_3_topography["C42.1"]
icd_10C92.1
who_classificationChronic myeloid leukaemia, BCR::ABL1-positive (per WHO 5th ed.) — chronic, accelerated, blast phase

Capacités

Notes

Etiologically-driven archetype (single causal driver: BCR-ABL1). TKI choice in chronic phase 1L is the central question, driven by ELTS risk + comorbidity matrix: imatinib for low-risk / elderly / cost-constrained; nilotinib or dasatinib or bosutinib for higher-risk young targeting deep molecular response + treatment-free remission; ponatinib / asciminib reserved for T315I or ≥3L. Response milestones by IS BCR-ABL1: ≤10% at 3 mo, ≤1% at 6 mo, ≤0.1% (MMR) at 12 mo. STUB — requires clinical co-lead signoff before publication. Myeloid expansion (heme).

Utilisé par

Pertinence thérapeutique

Algorithmes

Indication

Questionnaires

Signal d’alerte

Sources